Next Article in Journal
Multifocal Neuroblastoma and Central Hypoventilation in An Infant with Germline ALK F1174I Mutation
Previous Article in Journal
SARS-CoV-2 Infection during Pregnancy and Histological Alterations in the Placenta
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 12
Issue 9
10.3390/diagnostics12092259
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Association between High-Sensitivity Cardiac Troponin I and Clinical Prognosis of Neurosurgical and Neurocritically Ill Patients

by
Jung Hwa Lee
1,2,
Yun Im Lee
3,
Joonghyun Ahn
4 and
Jeong-Am Ryu
5,6,*
1
Department of Neurology, Ewha Women’s University Hospital, Ewha Women’s University College of Medicine, Seoul 07985, Korea
2
Department of Critical Care Medicine, Ewha Women’s University Hospital, Ewha Women’s University College of Medicine, Seoul 07985, Korea
3
Department of Internal Medicine, National Cancer Center, Goyang 10408, Korea
4
Statistic and Data Center, Clinical Research Institute, Samsung Medical Center, Seoul 06351, Korea
5
Department of Critical Care Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
6
Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea
*
Author to whom correspondence should be addressed.
Diagnostics 2022, 12(9), 2259; https://doi.org/10.3390/diagnostics12092259
Submission received: 23 August 2022 / Revised: 14 September 2022 / Accepted: 16 September 2022 / Published: 19 September 2022
(This article belongs to the Section Pathology and Molecular Diagnostics)
Browse Figures
Review Reports Versions Notes

Abstract

:
To investigate whether high-sensitivity troponin I (hs-TnI) elevation is associated with in-hospital mortality and major adverse cardiac events (MACEs) in neurosurgical and neurocritically ill patients. Among neurosurgical patients admitted to the intensive care unit (ICU) from January 2013 to December 2019, those whose serum hs-TnI levels were obtained within 7 days after ICU admission were included. Propensity score matching was used. Each patient with hs-TnI elevation was matched to a control patient. The primary endpoint was in-hospital mortality and the secondary outcome was MACEs. The hs-TnI elevation was shown in 848 (14.1%) of 6004 patients. After propensity score matching, 706 pairs of data were generated by 1:1 individual matching without replacement. In multivariable analysis of overall and propensity score-matched population, hs-TnI elevation was associated with in-hospital mortality (adjusted odds ratio (OR): 2.37, 95% confidence interval (CI): 1.68–3.33 and adjusted OR: 1.89, 95% CI: 1.28–2.81, respectively). In addition, hs-TnI elevation was associated with MACEs (adjusted OR: 2.73, 95% CI: 1.74–4.29 and adjusted OR: 2.64, 95% CI: 1.60–4.51, respectively). In this study, hs-TnI elevation was associated with in-hospital mortality and MACEs in neurosurgical and neurocritically ill patients.

1. Background

Perioperative myocardial injury is associated with major adverse cardiac events (MACEs) and clinical prognosis of patients with non-cardiac or non-vascular surgeries [1,2]. Many surgical patients experience MACEs during the perioperative period and the first year after surgery [1,3,4,5]. In particular, postoperative cardiac troponin elevation is important to predict prognosis of these surgical patients [1]. In addition, cardiac troponin elevation is associated with increased mortality and hospitalization in critically ill patients [6]. Regardless of the associated cardiovascular disease, cardiac troponin is a specific marker of myocardial injury and a predictor of prognosis [7,8,9]. From the Fourth Universal Definition of Myocardial Infarction, a diagnosis criteria of acute myocardial infarction includes the detection of an increase and/or decrease of a high-sensitivity troponin, with at least one value above the 99th percentile of the upper reference limit (URL) and at least one of the following: symptoms of myocardial ischemia, new ischemic changes in electrocardiogram, development of pathological Q waves on electrocardiogram, imaging evidence of loss of viable myocardium or new regional wall motion abnormality in a pattern consistent with an ischemic etiology or intracoronary thrombus detected on angiography or autopsy [10,11,12,13,14].
Most morbidity and mortality of neurosurgical patients may be due to neurosurgical or neurocritical illness, although cardiac injury might also contribute to their poor clinical prognosis [15,16,17]. Cardiac troponin elevation is also associated with prognosis of neurocritically ill patients with intracerebral hemorrhage or subarachnoid hemorrhage [15,17,18,19].
A limited number of studies have reported that clinical outcomes of neurosurgical and neurocritically ill patients are associated with high-sensitivity troponin I (hs-TnI) elevation [15,16,19]. Therefore, the objective of this study was to investigate whether hs-TnI elevation might be associated with in-hospital mortality and MACEs in patients admitted to a neurosurgical intensive care unit (ICU). In addition, we evaluated whether hs-TnI elevation per se was associated with poor prognosis when severity and factors other than hs-TnI elevation were controlled by propensity score matching.

2. Methods

2.1. Study Population

This was a retrospective, single-center, observational study. Patients who were admitted to the neurosurgical ICU in a tertiary referral hospital (Samsung Medical Center, Seoul, Korea) from January 2013 to December 2019 were eligible. This study was approved by the Institutional Review Board of Samsung Medical Center (approval number: SMC 2020-09-082). Included criteria were: (1) patients who were hospitalized in the neurosurgical ICU due to postoperative management or neurocritical illness and (2) those whose serum hs-TnI levels were obtained within seven days after ICU admission. Exclusion criteria were: (1) those with insufficient medical records, (2) those who had ‘do not resuscitate’ order, (3) those who were admitted to departments other than neurosurgery, and (4) those who were transferred to other hospitals or with unknown prognoses (Figure 1).

2.2. Definitions and Endpoints

In this study, baseline characteristics such as comorbidities, ICU management, and laboratory data were collected retrospectively using Clinical Data Warehouse. Our center constructed the “Clinical Data Warehouse Darwin-C” designed for investigators to search and retrieve de-identified medical records from electronic archives. It contains data pertaining to more than four million patients. Clinical and laboratory data were extracted from the Clinical Data Warehouse Darwin-C after finalizing the patient list in this study. Risk of surgery was defined according to the 2014 European Society of Cardiology/European Society of Anesthesiology (ESC/ESA) guidelines [20]. Perioperative management of patients followed institutional protocols based on current guidelines [9,20]. According to the institutional guideline, perioperative hs-TnI was measured for patients with more than moderate risk or undergoing moderate- to high-risk surgeries [9,20]. It was also measured at the discretion of attending clinicians for patients with mild risks [20]. An automated analyzer (Advia Centaur XP, Siemens Healthcare Diagnostics, Erlangen, Germany) with a highly sensitive immunoassay was used for hs-TnI measurement. The lowest limit of detection was 6 ng/L. The 99th percentile URL is 40 ng/L provided by the manufacturer. In this study, hs-TnI elevation was defined as an increase in hs-TnI above 40 ng/L within 7 days after ICU admission according to Fourth Universal Definition of Myocardial Infarction and the 99th-percentile URL provided by the manufacturer [9,11]. Acute Physiology and Chronic Health Evaluation (APACHE) II score was calculated based on the worst value recorded during the initial 24 h in the ICU admission [21,22]. If the patient was intubated, the verbal score of Glasgow Coma Scale (GCS) was estimated using eye and motor scores as reported previously [23]. MACEs were defined as non-fatal cardiac arrest, emergent coronary revascularization, acute coronary syndrome, stroke, congestive heart failure, atrial fibrillation (new onset or destabilization of pre-existing atrial fibrillation), major arrhythmia, cardiovascular death, and rehospitalization for cardiovascular reasons [1]. The primary endpoint was in-hospital mortality, and the secondary outcome was MACES.

2.3. Statistical Analyses

All data are presented as means ± standard deviations for continuous variables and frequencies and proportions for categorical variables. Data were compared using Student’s t-test for continuous variables and Chi-square test or Fisher’s exact test for categorical variables. Propensity score matching was used to control the selection bias and the confounding factor detected in this observational study. Each patient with hs-TnI elevation was matched to one control patient with the nearest neighbor matching within calipers determined by the propensity score. A caliper width of 0.2 of the standard deviation of the logit of the propensity score was used for the matching [24]. To determine the effectiveness of propensity score matching for controlling the differences between patients with and without hs-TnI elevation, standardized mean differences (SMDs) were calculated for each variable before and after matching. SMDs less than 10% indicated successful propensity scores matching and balancing between the two groups. To evaluate whether there was a difference in in-hospital mortality and MACEs according to the hs-TnI elevation, we performed multiple logistic regression with stepwise variable selection in the overall and matched population. In the overall population, we tried to obtain the result of correcting confounding through regression adjustment, and in the matching dataset, we performed doubly robust estimation to additionally correct the bias that might still exit after propensity score matching. The variables included in the multiple analyses were age, sex, comorbidities, cause of ICU admission, utilization of organ support modalities, including mechanical ventilators, continuous renal replacement therapy and vasopressors, ICP monitoring devices, hyperosmolar therapy, GCS, and APACHE II score on ICU admission. Cumulative mortality was calculated by Kaplan–Meier estimate and compared using a log-rank test. All tests were two-sided and p values less than 0.05 were considered statistically significant. All statistical analyses were performed with R Statistical Software (version 4.0.2; R Foundation for Statistical Computing, Vienna, Austria).

3. Results

3.1. Baseline Characteristics

A total of 12,743 patients were admitted to the neurosurgical ICU during the study period and 6004 patients were included in the final analysis. In the overall study population, hs-TnI elevation was shown in 848 (14.1%) patients (Figure 1). The mean age of all patients was 55.8 ± 15.6 years. There were 2698 (44.9%) male patients. Malignancy (50.5%) and hypertension (34.8) were the most common comorbidities. Elective vascular surgery (37.1%) and brain tumors (36.0%) were the most common reasons for ICU admission (Table 1). In the overall population, there were significant differences for variables of baseline characteristics between the two groups except for current smoking and the use of mannitol (Table 1). The mean value of maximum hs-TnI level was higher in the hs-TnI elevation group than in the normal hs-TnI group (4196.1 ± 31,274.7 ng/L vs. 8.7 ± 6.5 ng/L, p < 0.001). After propensity score matching, 706 pairs of data were generated by 1:1 individual matching without replacement. No significant imbalance was found in baseline characteristics between matched pairs (Table 1).

3.2. Clinical Outcomes

In the overall study population, rates of in-hospital mortality and 28-day mortality were higher in patients with hs-TnI elevation than in those without hs-TnI elevation (26.7% vs. 3.1% and 26.3% vs. 2.8%, both p < 0.001) (Table 1). Clinical outcomes in the propensity score-matched population were similar to those of the entire population. In the propensity score-matched population, rates of in-hospital mortality and 28-day mortality were also higher in the elevated hs-TnI group than in the normal hs-TnI group (19.3% vs. 14.4%, p = 0.019 and 19.0% vs. 13.2, p = 0.004, respectively). MACEs were more common in patients with hs-TnI elevation than in those without hs-TnI elevation in the overall population and the propensity score-matched population (6.6% vs. 1.1% and 7.9% vs. 2.4%, both p < 0.001) (Table 1).
In multivariable analysis of the overall and propensity score-matched population, hs-TnI elevation was associated with in-hospital mortality (adjusted odds ratio (OR): 2.37, 95% confidence interval (CI): 1.68–3.33 and adjusted OR: 1.89, 95% CI: 1.28–2.81, respectively). In addition, hs-TnI elevation was associated with MACES (adjusted OR: 2.73, 95% CI: 1.74–4.29 and adjusted OR: 2.64, 95% CI: 1.60–4.51, respectively) (Table 2).
In survival analysis, the mortality rates of patients with hs-TnI elevation were significantly higher than those of patients without hs-TnI elevation in the overall population and the propensity score-matched population (p < 0.001 and p = 0.008, respectively) (Figure 2).

4. Discussion

In this study, we investigated whether hs-TnI elevation was associated with mortality and MACEs in patients admitted to a neurosurgical ICU. Major findings of this study were as follows. First, elevated hs-TnI level was shown in 14.1% of neurosurgical patients in the overall population. Second, rates of in-hospital mortality and 28-day mortality were higher in patients with hs-TnI elevation than in those without hs-TnI elevation in the overall study population and the propensity score-matched population. Finally, multivariable analysis revealed that hs-TnI elevation was associated with in-hospital mortality and MACES in the overall and propensity score-matched populations.
Cardiac troponin is a regulatory protein that can lead to myocardial contraction by controlling calcium-mediated interaction with actin and myosin [6,25]. Destroyed cardiomyocytes can release cardiac troponin into the blood that can be detected using a commercially available immunoassay [6]. Postoperative myocardial injury is an independent predictor of cardiovascular complications and mortality within 30 days and 1 year in patients undergoing orthopedic or abdominal surgeries [1]. In particular, hs-TnI elevation is associated with worse cardiac outcomes after major surgeries [26]. In addition, elevated hs-TnI measurements among critically ill patients are associated with increased mortality and ICU length of stay [26,27].
In patients with subarachnoid hemorrhage, electrocardiographic abnormalities, including prolongation of QT interval and repolarization abnormalities, are commonly detected [15,18]. In particular, cardiac troponin elevation has been found in one-third of patients with subarachnoid hemorrhage known to be associated with increased mortality [15,19]. Cardiac troponin elevation is also associated with mortality in patients with surgically treated intracerebral hemorrhage and traumatic brain injury [15,28]. Under stressful conditions such as acute brain injury, stimulation of the hypothalamic paraventricular nucleus as the main control center of the hypothalamic–pituitary–adrenal axis can activate sympathetic output and lead to electrocardiographic abnormalities, arrhythmia, and myocardial injury [29]. In addition, activation of this axis after acute brain injury can cause a significant increase in catecholamines. The catecholamine surge hypothesis is the most widely accepted mechanism of brain–heart interaction [29]. Recent histological studies have shown that catecholamine-mediated myocardial injury may be a major pathophysiology of neurocritical illness [15,16,17,30] (Figure 3). In particular, the catecholamine surge leads to activation of cyclic adenosine monophosphate (cAMP) in myocytes. cAMP activation causes excessive Ca++ influx and altered actin–myosin interaction. The actin–myosin interaction in cardiac muscle can be prolonged beyond its physical integrity [31]. As a result, the catecholamine stimulation surge can lead to myofibrillar degeneration and contraction band necrosis [32]. These band necrotic lesions in sub-endocardium are also associated with malignant arrhythmias by involving the conducting tissue [33]. In addition, the catecholamine surge can lead to increased potassium outflow through delayed rectifier channels. These changes lead to shortened and excessive heterogeneity of action potential duration causing disturbance of rate and rhythm. Eventually, the catecholamine surge causes myofibril necrosis [31]. Therefore, cardiac injury could be accompanied by neurosurgical or neurocritical illness. It is known to be associated with clinical prognosis [15,16,17,28,30].
Neurosurgical patients with severe brain injury are more likely to develop cardiac injury and MACEs compared to those with benign diseases. Therefore, it is not easy to determine whether elevated hs-TnI itself is associated with a poor prognosis or neurosurgical patients with elevated hs-TnI will show poor prognosis because of their neurocritical illness. Therefore, a propensity score matching method was used to adjust for this confounder in this study. In brief, hs-TnI elevation was significantly associated with poor clinical outcomes of neurosurgical and neurocritically ill patients. Finally, cardiac injury may also be a contributing factor of poor clinical outcomes, although most of the morbidity and mortality could be arising from neurocritical illness [15,16,17].
This study has several limitations. First, this was a retrospective review of medical records and data extracted from the Clinical Data Warehouse. The nonrandomized nature of registry data might have resulted in a selection bias. Second, laboratory tests including hs-TnI levels were protocol-based for patients with perioperative neurosurgery. They were performed occasionally by non-protocol methods for neurocritically ill patients without neurosurgery. Third, the pathophysiology of acute coronary syndrome could not be determined for a few patients. Cardiac catheterization was not performed in these sick patients because intrahospital transport was impossible due to severe illness. Finally, the distribution of neurosurgical diseases differed from that of the general neurosurgical ICU and the proportion of patients with brain tumors was particularly high.

5. Conclusions

In this study, hs-TnI elevation was associated with in-hospital mortality and MACEs in neurosurgical and neurocritically ill patients. Eventually, perioperative or neurocritical illness-associated cardiac injury could be associated with clinical outcomes of neurosurgical and neurocritically ill patients.

Author Contributions

Conceptualization, J.H.L. and J.-A.R.; Data curation, J.H.L. and Y.I.L.; Investigation, J.H.L. and J.-A.R.; Methodology, J.A. and J.-A.R.; Project administration, Y.I.L.; Resources, J.-A.R.; Supervision, J.-A.R.; Validation, J.A. and J.-A.R.; Visualization, J.H.L. and J.A.; Writing—original draft, J.H.L. and J.-A.R.; Writing—review & editing, J.-A.R. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was approved by the Institutional Review Board of Samsung Medical Center (approval number: SMC 2020-09-082). Patients’ records were reviewed and published according to the Declaration of Helsinki. The requirement of informed consent was waived due to the retrospective nature of this study.

Informed Consent Statement

Not applicable. This study did not contain individual or personal data in any form (including individual details, images or videos).

Data Availability Statement

Our data are available on Harvard Dataverse Network (http://dx.doi.org/10.7910/DVN/9HU70P, accessed on 9 December 2020).

Acknowledgments

We would like to thank the nursing director of the neurosurgical intensive care unit, Hye Jung Kim, for her excellent advice and fruitful discussions.

Conflicts of Interest

The authors declare that they have no conflict of interest.

Abbreviations

APACHE, acute physiology and chronic health evaluation; CI, confidence interval; cAMP, cyclic adenosine monophosphate; hs-TnI, high-sensitivity troponin I; GCS, Glasgow coma scale; ICP, intracranial pressure; ICU, intensive care unit; MACEs, major adverse cardiac events; OR, odds ratio; SMD, standardized mean difference.

References

  1. Ekeloef, S.; Alamili, M.; Devereaux, P.J.; Gogenur, I. Troponin elevations after non-cardiac, non-vascular surgery are predictive of major adverse cardiac events and mortality: A systematic review and meta-analysis. Br. J. Anaesth. 2016, 117, 559–568. [Google Scholar] [CrossRef] [PubMed]
  2. Oscarsson, A.; Fredrikson, M.; Sorliden, M.; Anskar, S.; Gupta, A.; Swahn, E.; Eintrei, C. Predictors of cardiac events in high-risk patients undergoing emergency surgery. Acta Anaesthesiol. Scand. 2009, 53, 986–994. [Google Scholar] [CrossRef]
  3. Devereaux, P.J.; Xavier, D.; Pogue, J.; Guyatt, G.; Sigamani, A.; Garutti, I.; Leslie, K.; Rao-Melacini, P.; Chrolavicius, S.; Yang, H.; et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: A cohort study. Ann. Intern. Med. 2011, 154, 523–528. [Google Scholar] [CrossRef]
  4. Devereaux, P.J.; Mrkobrada, M.; Sessler, D.I.; Leslie, K.; Alonso-Coello, P.; Kurz, A.; Villar, J.C.; Sigamani, A.; Biccard, B.M.; Meyhoff, C.S.; et al. Aspirin in patients undergoing noncardiac surgery. N. Engl. J. Med. 2014, 370, 1494–1503. [Google Scholar] [CrossRef] [PubMed]
  5. Devereaux, P.J.; Chan, M.T.; Alonso-Coello, P.; Walsh, M.; Berwanger, O.; Villar, J.C.; Wang, C.Y.; Garutti, R.I.; Jacka, M.J.; Sigamani, A.; et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA 2012, 307, 2295–2304. [Google Scholar] [PubMed]
  6. Lim, W.; Qushmaq, I.; Devereaux, P.J.; Heels-Ansdell, D.; Lauzier, F.; Ismaila, A.S.; Crowther, M.A.; Cook, D.J. Elevated cardiac troponin measurements in critically ill patients. Arch. Intern. Med. 2006, 166, 2446–2454. [Google Scholar] [CrossRef]
  7. Omland, T.; de Lemos, J.A.; Sabatine, M.S.; Christophi, C.A.; Rice, M.M.; Jablonski, K.A.; Tjora, S.; Domanski, M.J.; Gersh, B.J.; Rouleau, J.L.; et al. A sensitive cardiac troponin T assay in stable coronary artery disease. N. Engl. J. Med. 2009, 361, 2538–2547. [Google Scholar] [CrossRef]
  8. Ford, I.; Shah, A.S.; Zhang, R.; McAllister, D.A.; Strachan, F.E.; Caslake, M.; Newby, D.E.; Packard, C.J.; Mills, N.L. High-Sensitivity Cardiac Troponin, Statin Therapy, and Risk of Coronary Heart Disease. J. Am. Coll. Cardiol. 2016, 68, 2719–2728. [Google Scholar] [CrossRef]
  9. Park, J.; Hyeon, C.W.; Lee, S.H.; Kim, J.; Kwon, J.H.; Yang, K.; Min, J.J.; Lee, J.H.; Lee, S.M.; Yang, J.H.; et al. Mildly Elevated Cardiac Troponin below the 99th-Percentile Upper Reference Limit after Noncardiac Surgery. Korean Circ. J. 2020, 50, 925–937. [Google Scholar] [CrossRef]
  10. Collet, J.P.; Thiele, H.; Barbato, E.; Barthélémy, O.; Bauersachs, J.; Bhatt, D.L.; Dendale, P.; Dorobantu, M.; Edvardsen, T.; Folliguet, T.; et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 2021, 42, 1289–1367. [Google Scholar] [CrossRef]
  11. Thygesen, K.; Alpert, J.S.; Jaffe, A.S.; Chaitman, B.R.; Bax, J.J.; Morrow, D.A.; White, H.D.; Group, E.S.D. Fourth universal definition of myocardial infarction. Eur. Heart J. 2018, 40, 237–269. [Google Scholar] [CrossRef] [PubMed]
  12. Chaulin, A. Cardiac Troponins: Contemporary Biological Data and New Methods of Determination. Vasc. Health Risk Manag. 2021, 17, 299–316. [Google Scholar] [CrossRef] [PubMed]
  13. Clerico, A.; Zaninotto, M.; Padoan, A.; Masotti, S.; Musetti, V.; Prontera, C.; Ndreu, R.; Zucchelli, G.; Passino, C.; Migliardi, M.; et al. Evaluation of analytical performance of immunoassay methods for cTnI and cTnT: From theory to practice. Adv. Clin. Chem. 2019, 93, 239–262. [Google Scholar] [PubMed]
  14. Chaulin, A.M. Cardiac Troponins Metabolism: From Biochemical Mechanisms to Clinical Practice (Literature Review). Int. J. Mol. Sci. 2021, 22, 10928. [Google Scholar] [CrossRef]
  15. Garrett, M.C.; Komotar, R.J.; Starke, R.M.; Doshi, D.; Otten, M.L.; Connolly, E.S. Elevated troponin levels are predictive of mortality in surgical intracerebral hemorrhage patients. Neurocrit. Care 2010, 12, 199–203. [Google Scholar] [CrossRef]
  16. Connor, R.C. Myocardial damage secondary to brain lesions. Am. Heart J. 1969, 78, 145–148. [Google Scholar] [CrossRef]
  17. Doshi, R.; Neil-Dwyer, G. Hypothalamic and myocardial lesions after subarachnoid haemorrhage. J. Neurol. Neurosurg. Psychiatry 1977, 40, 821–826. [Google Scholar] [CrossRef]
  18. Zaroff, J.G.; Rordorf, G.A.; Ogilvy, C.S.; Picard, M.H. egional patterns of left ventricular systolic dysfunction after subarachnoid hemorrhage: Evidence for neurally mediated cardiac injury. J. Am. Soc. Echocardiogr. Off. Publ. Am. Soc. Echocardiogr. 2000, 13, 774–779. [Google Scholar] [CrossRef]
  19. Naidech, A.M.; Kreiter, K.T.; Janjua, N.; Ostapkovich, N.D.; Parra, A.; Commichau, C.; Fitzsimmons, B.F.; Connolly, E.S.; Mayer, S.A. Cardiac troponin elevation, cardiovascular morbidity, and outcome after subarachnoid hemorrhage. Circulation 2005, 112, 2851–2856. [Google Scholar] [CrossRef]
  20. Kristensen, S.D.; Knuuti, J. New ESC/ESA Guidelines on non-cardiac surgery: Cardiovascular assessment and management. Eur. Heart J. 2014, 35, 2344–2345. [Google Scholar] [CrossRef]
  21. Knaus, W.A.; Draper, E.A.; Wagner, D.P.; Zimmerman, J.E. APACHE II: A severity of disease classification system. Crit. Care Med. 1985, 13, 818–829. [Google Scholar] [CrossRef] [PubMed]
  22. Capuzzo, M.; Valpondi, V.; Sgarbi, A.; Bortolazzi, S.; Pavoni, V.; Gilli, G.; Candini, G.; Gritti, G.; Alvisi, R. Validation of severity scoring systems SAPS II and APACHE II in a single-center population. Intensive Care Med. 2000, 26, 1779–1785. [Google Scholar] [CrossRef] [PubMed]
  23. Meredith, W.; Rutledge, R.; Fakhry, S.M.; Emery, S.; Kromhout-Schiro, S. The conundrum of the Glasgow Coma Scale in intubated patients: A linear regression prediction of the Glasgow verbal score from the Glasgow eye and motor scores. J. Trauma 1998, 44, 839–845. [Google Scholar] [CrossRef] [PubMed]
  24. Austin, P.C. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm. Stat. 2011, 10, 150–161. [Google Scholar] [CrossRef]
  25. Adams, J.E., 3rd; Abendschein, D.R.; Jaffe, A.S. Biochemical markers of myocardial injury. Is MB creatine kinase the choice for the 1990s? Circulation 1993, 88, 750–763. [Google Scholar] [CrossRef]
  26. Noordzij, P.G.; van Geffen, O.; Dijkstra, I.M.; Boerma, D.; Meinders, A.J.; Rettig, T.C.; Eefting, F.D.; van Loon, D.; van de Garde, E.M.; van Dongen, E.P. High-sensitive cardiac troponin T measurements in prediction of non-cardiac complications after major abdominal surgery. Br. J. Anaesth. 2015, 114, 909–918. [Google Scholar] [CrossRef]
  27. Gillies, M.A.; Shah, A.S.; Mullenheim, J.; Tricklebank, S.; Owen, T.; Antonelli, J.; Strachan, F.; Mills, N.L.; Pearse, R.M. Perioperative myocardial injury in patients receiving cardiac output-guided haemodynamic therapy: A substudy of the OPTIMISE Trial. Br. J. Anaesth. 2015, 115, 227–233. [Google Scholar] [CrossRef]
  28. Rimaz, S.; Ashraf, A.; Marzban, S.; Haghighi, M.; Zia Ziabari, S.M.; Biazar, G.; Rimaz, S.; Omidi, S. Significance of Cardiac Troponin I Elevation in Traumatic Brain Injury Patients. Anesth. Pain Med. 2019, 9, e90858. [Google Scholar] [CrossRef]
  29. Chen, Z.; Venkat, P.; Seyfried, D.; Chopp, M.; Yan, T.; Chen, J. Brain-Heart Interaction: Cardiac Complications After Stroke. Circ. Res. 2017, 121, 451–468. [Google Scholar] [CrossRef]
  30. Todd, G.L.; Baroldi, G.; Pieper, G.M.; Clayton, F.C.; Eliot, R.S. Experimental catecholamine-induced myocardial necrosis. I. Morphology, quantification and regional distribution of acute contraction band lesions. J. Mol. Cell. Cardiol. 1985, 17, 317–338. [Google Scholar] [CrossRef]
  31. Ibrahim, M.S.; Samuel, B.; Mohamed, W.; Suchdev, K. Cardiac Dysfunction in Neurocritical Care: An Autonomic Perspective. Neurocrit. Care 2019, 30, 508–521. [Google Scholar] [CrossRef] [PubMed]
  32. Samuels, M.A. Neurogenic heart disease: A unifying hypothesis. Am. J. Cardiol. 1987, 60, 15j–19j. [Google Scholar] [CrossRef]
  33. Samuels, M.A. The brain-heart connection. Circulation 2007, 116, 77–84. [Google Scholar] [CrossRef] [PubMed]
Diagnostics 12 02259 g001 550
Figure 1. Study flow chart. ICU, intensive care unit; hs-TnI, high-sensitivity troponin I.
Figure 1. Study flow chart. ICU, intensive care unit; hs-TnI, high-sensitivity troponin I.
Diagnostics 12 02259 g001
Diagnostics 12 02259 g002 550
Figure 2. Kaplan–Meier survival analyses in the overall population (A) and the propensity score-matched population. (B) The mortality rates of the patients with high-sensitivity troponin I (hs-TnI) elevation were significantly higher compared with those without hs-TnI elevation in the overall population and the propensity score-matched population (p < 0.001 and p = 0.008, respectively).
Figure 2. Kaplan–Meier survival analyses in the overall population (A) and the propensity score-matched population. (B) The mortality rates of the patients with high-sensitivity troponin I (hs-TnI) elevation were significantly higher compared with those without hs-TnI elevation in the overall population and the propensity score-matched population (p < 0.001 and p = 0.008, respectively).
Diagnostics 12 02259 g002
Diagnostics 12 02259 g003 550
Figure 3. The mechanisms of cardiomyocyte damage and increased troponins in neurosurgical and neurocritically ill patients. The catecholamine surge resulting from activation of the hypothalamic–pituitary–adrenal axis and sympathetic nerve leads to myocardial damage.
Figure 3. The mechanisms of cardiomyocyte damage and increased troponins in neurosurgical and neurocritically ill patients. The catecholamine surge resulting from activation of the hypothalamic–pituitary–adrenal axis and sympathetic nerve leads to myocardial damage.
Diagnostics 12 02259 g003
Table
Table 1. Baseline characteristics of study population.
Table 1. Baseline characteristics of study population.
Overall Study PopulationPropensity Score-Matched Population
No Elevation
(n = 5156)		Elevation
(n = 848)		p ValueSMDNo Elevation (n = 706)Elevation (n = 706)p ValueSMD
Patient demographics
 Age (year)54.7 ± 15.362.1 ± 15.9<0.0010.47162.0 ± 14.661.8 ± 16.00.7700.016
 Sex, male2266 (43.9)432 (50.9)<0.0010.14349 (49.4)366 (51.8)0.3940.048
Comorbidities
 Malignancy2657 (51.5)373 (44.0)<0.0010.152350 (49.6)344 (48.7)0.7900.017
 Hypertension1678 (32.5)412 (48.6)<0.0010.331341 (48.3)347 (49.2)0.7900.017
 Diabetes mellitus567 (11.0)162 (19.1)<0.0010.228111 (15.7)141 (20.0)0.0440.111
 Chronic kidney disease154 (3.0)95 (11.2)<0.0010.32461 (8.6)69 (9.8)0.5190.039
 Cardiovascular disease92 (1.8)88 (10.4)<0.0010.36657 (8.1)65 (9.2)0.5070.040
 Chronic liver disease99 (1.9)31 (3.7)0.0020.10624 (3.4)25 (3.5)0.9990.008
Behavioral risk factors
 Current alcohol consumption1257 (24.4)172 (20.3)0.0110.098151 (21.4)147 (20.8)0.8450.014
 Current smoking577 (11.2)90 (10.6)0.6620.01983 (11.8)77 (10.9)0.6750.027
Cause of ICU admission <0.0011.132 0.9070.098
 Brain tumor1961 (38.0)200 (23.6) 200 (28.3)196 (27.8)
 Elective vascular surgery2137 (41.4)93 (11.0) 74 (10.5)93 (13.2)
 Intracerebral hemorrhage234 (4.5)160 (18.9) 138 (19.5)129 (18.3)
 Traumatic brain injury221 (4.3)155 (18.3) 122 (17.3)116 (16.4)
 Subarachnoid hemorrhage202 (3.9)144 (17.0) 100 (14.2)100 (14.2)
 Spinal surgery213 (4.1)29 (3.4) 25 (3.5)28 (4.0)
 Central nervous system infection41 (0.8)10 (1.2) 7 (1.0)8 (1.1)
 Cerebral infarction29 (0.6)18 (2.1) 18 (2.5)14 (2.0)
 Others118 (2.3)39 (4.6) 22 (3.1)22 (3.1)
APACHE II score on ICU admission 3.2 ± 4.37.54 ± 7.83<0.0010.6916.0 ± 6.36.41 ±7.040.2540.061
Glasgow coma scale on ICU admission14.6 ± 1.512.2 ± 4.2<0.0010.77613.2 ± 3.313.1 ± 3.40.7060.020
ICU management
 Use of vasopressors 112 (2.2)103 (12.1)<0.0010.39468 (9.6)73 (10.3)0.7230.024
 Mechanical ventilation 775 (15.0)504 (59.4)<0.0011.034374 (53.0)367 (52.0)0.7490.020
 Continuous renal replacement therapy 11 (0.2)46 (5.4)<0.0010.31910 (1.4)13 (1.8)0.6740.034
 ICP monitoring 376 (7.3)170 (20.0)<0.0010.378137 (19.4)139 (19.7)0.9460.007
 Use of mannitol a2250 (43.6)349 (41.2)0.1890.05295 (41.8)286 (40.5)0.6650.026
 Use of glycerin a508 (9.9)267 (31.5)<0.0010.554207 (29.3)209 (29.6)0.9530.006
Clinical outcomes b
 In-hospital mortality158 (3.1)226 (26.7)<0.001 102 (14.4)136 (19.3)0.019
 28-day mortality144 (2.8)223 (26.3)<0.001 93 (13.2)134 (19.0)0.004
 ICU mortality87 (1.7)163 (19.2)<0.001 68 (9.6)83 (11.8)0.228
 ICU length of stay (hour)57.0 ± 334.2131.8 ± 200.2<0.001 145.3 ± 827.1132.8 ± 203.30.695
 Hospital length of stay (day)22.9 ± 93.945.7 ± 205.1<0.001 55.7 ± 237.738.6 ± 59.80.065
Major adverse cardiac events b57 (1.1)56 (6.6)<0.001 17 (2.4)56 (7.9)<0.001
 New onset arrhythmia53 (1.0)24 (2.8) 16 (2.3)24 (3.4)
 Heart failure2 (0.0)15 (1.8) 0 (0.0)15 (2.1)
 Acute coronary syndrome1 (0.0)12 (1.4) 0 (0.0)12 (1.7)
 Cardiac arrest1 (0.0)5 (0.6) 1 (0.1)5 (0.7)
 Cardiovascular death0 (0.0)15 (1.8) 0 (0.0)15 (2.1)
Data are presented as numbers (%) or means ± standard deviations. a Some patients received more than one hyperosmolar agent. b Variables are not retained in propensity score matching. APACHE, Acute Physiology and Chronic Health Evaluation; ICP, intracranial pressure; ICU, intensive care unit; SMD, standardized mean difference.
Table
Table 2. The relationship between elevated high-sensitivity troponin I (hs-TnI) and clinical outcomes of the overall and propensity score-matched population.
Table 2. The relationship between elevated high-sensitivity troponin I (hs-TnI) and clinical outcomes of the overall and propensity score-matched population.
hs-TnI Elevation within 7 Daysa Adjusted Odds Ratio (95% CI)p Value
In-hospital mortality
 Overall population2.37 (1.68–3.33)< 0.001
 Propensity score-matched population1.89 (1.28–2.81)0.002
Major adverse cardiac events
 Overall population2.73 (1.74–4.29)< 0.001
 Propensity score-matched population2.64 (1.60–4.51)< 0.001
a Adjusted for age, sex, comorbidities, cause of ICU admission, utilization of organ support modalities, use of invasive ICP monitoring device, hyperosmolar therapy, and APACHE II score on ICU admission. CI, confidence interval; APACHE, Acute Physiology and Chronic Health Evaluation; ICP, intracranial pressure; ICU, intensive care unit.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Share and Cite

MDPI and ACS Style

Lee, J.H.; Lee, Y.I.; Ahn, J.; Ryu, J.-A. Association between High-Sensitivity Cardiac Troponin I and Clinical Prognosis of Neurosurgical and Neurocritically Ill Patients. Diagnostics 2022, 12, 2259. https://doi.org/10.3390/diagnostics12092259

AMA Style

Lee JH, Lee YI, Ahn J, Ryu J-A. Association between High-Sensitivity Cardiac Troponin I and Clinical Prognosis of Neurosurgical and Neurocritically Ill Patients. Diagnostics. 2022; 12(9):2259. https://doi.org/10.3390/diagnostics12092259

Chicago/Turabian Style

Lee, Jung Hwa, Yun Im Lee, Joonghyun Ahn, and Jeong-Am Ryu. 2022. "Association between High-Sensitivity Cardiac Troponin I and Clinical Prognosis of Neurosurgical and Neurocritically Ill Patients" Diagnostics 12, no. 9: 2259. https://doi.org/10.3390/diagnostics12092259

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop